The Ministry of Finance (MOF) on April 27 called for reexamining the purpose of a key price maintenance premium for on-patent medicines, rapping the premium for being granted merely based on declines in drugs’ market prices and not on their…
To read the full story
Related Article
- MOF Panel Recommends Generic Target of 80% by FY2017-End
June 2, 2015
- MOF Presses for 80% Generic Share Target by FY2017
April 28, 2015
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





